MOLECULAR PHARMACOLOGY IN CHINA

Statins Attenuate Activation of the NLRP3 Inflammasome by Oxidized LDL or TNFα in Vascular Endothelial Cells through a PXR-Dependent Mechanism

Shaolan Wang, Xinya Xie, Ting Lei, Kang Zhang, Baochang Lai, Zihui Zhang, Youfei Guan, Guangmei Mao, Lei Xiao, and Nanping Wang

Cardiovascular Research Center, School of Medicine, Xi’an Jiaotong University, Xi’an, People’s Republic of China (S.W., X.X., T.L., K.Z., B.L., Z.Z., L.X., N.W.); The Advanced Institute of Medical Sciences, Dalian Medical University, Dalian, People’s Republic of China (Y.G., N.W.); and Department of Quantitative Health Sciences, Cleveland Clinic, Cleveland, Ohio (G.M.)

Received December 25, 2016; accepted May 22, 2017

ABSTRACT

Excessive activation of the NLRP3 inflammasome is implicated in cardiovascular diseases. Statins exert an anti-inflammatory effect independent of their cholesterol-lowering effect. This study investigated the potential role of statins in the activation of the NLRP3 inflammasome in endothelial cells (ECs). Western blotting and quantitative reverse-transcription polymerase chain reaction showed that oxidized low-density lipoprotein (ox-LDL) or tumor necrosis factor α (TNFα) activated the NLRP3 inflammasome in ECs. Simvastatin or mevastatin significantly suppressed ox-LDL-mediated NLRP3 inflammasome activation via the pregnane X receptor (PXR). In addition, PXR agonists (rifampicin and SR12813) or overexpression of a constitutively active PXR markedly suppressed the NLRP3 inflammasome activation. Conversely, PXR knockdown abrogated the suppressive effect of rifampicin on NLRP3 inflammasome activation. Knockdown of the constitutive subunit of the inflammasome inhibited nuclear factor-κB binding to the promoter regions of the human NLRP3 gene. Collectively, these results demonstrate that the statin activation of PXR inhibits the activation of NLRP3 inflammasome in response to atherogenic stimuli such as ox-LDL and TNFα in ECs, providing a new mechanism for the cardiovascular benefit of statins.

Introduction

Endothelial cells (ECs) exert critical functions in maintaining homeostasis in the vascular system. Endothelial inflammation is a major contributor to endothelial dysfunction in cardiovascular disorders such as hypertension, diabetes, and atherosclerosis (Davignon and Ganz, 2004). Interleukin (IL)-1β is a key proinflammatory mediator involved in endothelial dysfunction and serves as a major atherogenic factor (Fearon and Fearon, 2008). The production of active IL-1β is tightly controlled through the formation and activation of the NLRP3 inflammasome. The NLRP3 inflammasome, the best-characterized family member, is a multiprotein complex consisting of NLRP3, caspase-1, and the adaptor ASC (PYCARD). Activation of the NLRP3 inflammasome promotes the cleavage of caspase-1 and the maturation of IL-1β and IL-18. Excessive activation of the NLRP3 inflammasome and the ensuing IL-1β secretion have recently emerged as central mechanisms in the pathogenesis of metabolic diseases, including type II diabetes, obesity, and atherosclerosis (Mitroulis et al., 2010; Strowig et al., 2012). Activation of NLRP3 in ECs, triggered by dyslipidemia, disturbed blood flow, and visfatin, may contribute to the development of atherosclerosis and restenosis (Xia et al., 2014; Xiao et al., 2013).

Statins comprise a class of cholesterol-lowering drugs widely used in the treatment of hypercholesterolemia and

ABBREVIATIONS: Ad, adenovirus; Ad-VP-PXR, adenovirus encoding constitutively active pregnane X receptor; BAEC, bovine aortic endothelial cell; CAD, coronary artery disease; ChIP, chromatin immunoprecipitation; EC, endothelial cell; HUVEC, human umbilical vein endothelial cell; IL, interleukin; LDL, low-density lipoprotein; LOX-1, lectin-like oxidized low-density lipoprotein receptor; Luc, luciferase; NF-κB, nuclear factor-κB; ox-LDL, oxidized-low-density lipoprotein; PXR, pregnane X receptor; PPRE, PXR-responsive element; qRT-PCR, quantitative reverse-transcription polymerase chain reaction; ROS, reactive oxygen species; siRNA, small interfering RNA; TNFα, tumor necrosis factor α; tTA, tetracycline-responsive transactivator; VP-PPXR, constitutively active pregnane X receptor.
coronary artery diseases (CADs). Acting as 3-hydroxy-3-methylglutaryl CoA reductase inhibitors, statins increase the expression of low-density lipoprotein (LDL) receptor in the liver, resulting in increased cholesterol uptake and lowered circulating cholesterol levels. In addition, statins have immunomodulatory and anti-inflammatory properties (Spyridopoulos et al., 2004; Morimoto et al., 2006). Statins also improve endothelial function (Kesavan et al., 2014). Recent studies have shown that statins affect the anti-NLRP3 in patients with cardiovascular disease. A randomized clinical study showed that atorvastatin markedly diminished NLRP3 inflammasome levels in CAD patients (Satoh et al., 2014). In monocytic THP-1 cells, atorvastatin inhibited activation of the NLRP3 inflammasome (Satoh et al., 2014). Rosuvastatin has been reported (Luo et al., 2014) to alleviate diabetic cardiomyopathy by inhibiting NLRP3 inflammasome and mitogen-activated protein kinase pathways in a rat model of type II diabetes. However, the mechanisms by which statins regulate NLRP3 inflammasome remain largely unknown.

The nuclear pregnane X receptor [PXR (NR1I2)] is a member of the nuclear receptor superfamily and functions as the body’s defense against xenobiotics, including pollutants, drugs, dietary compounds, and their metabolites (Kliewer et al., 2002). In addition to its conventional role in xenobiotic metabolism in liver and intestines, we and others (Wang et al., 2013) also found that PXR is expressed in the vasculature, where it regulates vascular detoxification and inflammation. In particular, PXR suppresses the expression of proinflammatory adhesion molecules, such as vascular cell adhesion molecule-1 and endothelial selectin in response to TNFα and lipopolysaccharide in ECs. Overexpression of a constitutively active PXR (VP-PXR) in rat carotid arteries attenuated proinflammatory responses (Wang et al., 2013). Notably, PXR appears to orchestrate the regulated expression of the key genes responsible for detoxification and innate immunity programs in ECs (Wang et al., 2014). Statins have been known to activate PXR (Howe et al., 2011). Thus, we sought to investigate the effects of statins in the activation of NLRP3 inflammasomes in ECs and the underlying mechanisms.

### Materials and Methods

**Cells and Reagents.** Human umbilical vein ECs (HUVECs) were cultured in medium 199 containing heparin (0.1 mg/ml), acidic fibroblast growth factor (10 ng/ml), L-glutamine (2 mM), penicillin (100 U/ml), streptomycin (100 U/ml), and 20% fetal bovine serum. Bovine aortic ECs (BAECs) were maintained in Dulbecco’s modified Eagle’s medium with 10% fetal bovine serum, penicillin (100 U/ml), and streptomycin (100 U/ml). Rifampicin was from Cayman (Ann Arbor, MI). Antibodies against NLRP3 and nuclear factor-κB (NF-κB) p65 were from Abcam (Cambridge, UK). Antibody to caspase-1 was

<table>
<thead>
<tr>
<th>Primer</th>
<th>Forward (5’ to 3’)</th>
<th>Reverse (5’ to 3’)</th>
</tr>
</thead>
<tbody>
<tr>
<td>-847 to -838</td>
<td>CAAGGAGGGGACACTTCCAA</td>
<td>TGAAAAAGGAGCAGCCACAG</td>
</tr>
<tr>
<td>-186 to -157</td>
<td>ACTGAGTGATCATGCTTATA</td>
<td>TCTCCGTATCCATCAGGGGT</td>
</tr>
<tr>
<td>-110 to -101</td>
<td>ACCGAGACGTCTTTGGAC</td>
<td>GCTGAGCTTCGAGATGCC</td>
</tr>
</tbody>
</table>

### Fig. 1. Effects of statins on ox-LDL- or TNFα-induced NLRP3 inflammasome activation in ECs. (A) HUVECs were treated with ox-LDL (0-200 μg/ml) or TNFα (0-10 ng/ml) for 12 hours. Cell lysates were analyzed for NLRP3 and caspase-1 proteins by Western blotting. (B) Total RNA was extracted and subjected to qRT-PCR for the assessment of NLRP3 mRNA. (C) HUVECs were pretreated with simvastatin (SIM; 0.5 μM) or mevastatin (Mev; 5 μM) for 12 hours before stimulation with ox-LDL (100 μg/ml) or TNFα (10 ng/ml) for 12 hours. Cell lysates were analyzed for NLRP3 and caspase-1 protein levels by Western blotting. (D) Total RNA was extracted and subjected to qRT-PCR for the assessment of NLRP3 mRNA. Data represent the mean ± SD, n = 3–5, *P < 0.05, **P < 0.01 versus control; ##P < 0.01 versus ox-LDL.
from Cell Signaling Technology (Danvers, MA). Antibodies against PXR, LeBo, IgG, gyceraldehyde-3-phosphate dehydrogenase, histone, and β-actin were from Santa Cruz Biotechnology (Santa Cruz, CA). Antibody against lectin-like ox-LDL receptor (LOX-1) was from Sigma-Aldrich (St. Louis, MO). Human recombinant TNF antibody against lectin-like ox-LDL receptor (LOX-1) was from R&D Systems (Minneapolis, MN). Reactive oxygen species (ROS) inhibitors (NAC and DPI) were from Sigma-Aldrich. Oxidized low-density lipoprotein (ox-LDL) was from Anhui Yiyuan Biotechnology Co., Ltd. (Guangzhou, People’s Republic of China). Other reagents were from Sigma-Aldrich.

Quantitative Reverse Transcriptase Polymerase Chain Reaction. Total RNA was isolated using TRIzol (Invitrogen, Carlsbad, CA), then reverse transcribed into cDNA by using the iScript cDNA Synthesis Kit (BIO-RAD, Hercules, CA). Quantitative reverse-transcription polymerase chain reaction (qRT-PCR) was performed by using SYBR Green Supermixes (BIO-RAD) and a 7500 Real-time PCR Machine (Applied Biosystems, Foster City, CA). Fold changes of gene expression were calculated using the 2^(-ΔΔCt) method. The following qRT-PCR primers were used: NLRP3 forward primer, 5'-TCTCCCTGCATGAGCGCCAAG-3', reverse primer, 5'-CAGCAAAACTGGAAGGAAG-3', LOX-1 forward primer, 5'-TTACCTCCATGTTGTTGCC-3', reverse primer, 5'-AGCTCTTCTGCTGTTGCC-3', MDR1 forward primer, 5'-CCCTTGAAGACA-GCCCTCATA-3', reverse primer, 5'-TCATACTGAGATTCTCACC-3', and gyceraldehyde-3-phosphate dehydrogenase (GAPDH) forward primer, 5'-ACCACATCCTAGGCAACATC-3', reverse primer, 5'-TCACACACCCTGGTCTGCTA-3'. Glyceraldehyde-3-phosphate dehydrogenase was used as an internal control.

Western Blotting. Protein samples were extracted with lysis buffer (10 mM Tris-HCl at pH 7.4, 150 mM NaCl, and 0.1% Triton X-100) supplemented with a protease inhibitor cocktail (Roche Diagnostics, Indianapolis, IN). Cytoplasmic proteins were extracted with hypotonic lysis buffer (10 mM Tris-HCl, pH 7.5, 1.5 mM MgCl2, 10 mM KCl, and 0.5% NP40). Nuclear proteins were extracted with high-salt buffer (20 mM Tris-HCl, 1.5 mM MgCl2, 420 mM NaCl, 10% glycerol, and 0.2 mM EGTA). BCA protein assay reagents (Pierce, Rockford, IL) were used to assess protein concentration. Protein samples were separated on SDS-PAGE and transferred onto a polyvinylidene difluoride membrane. Immunoblotting was performed with primary antibodies and appropriate horseradish peroxidase-conjugated secondary antibodies, visualized using an enhanced chemiluminescence system.

Adenoviral Vectors and Infection. Recombinant adenoviruses (Ads) encoding VP-PXR (Ad-VP-PXR), Ad-αTA [an Ad expressing tetracycline-responsive transactivator (tTA)], Ad-LacZ (Ads) encoding VP-PXR (Ad-VP-PXR), Ad-tTA [an Ad expressing β-galactosidase], and Ad-LeBo were as previously described (Wang et al., 2013). HUVECs were coinfected with Ad-αTA and Ad-VP-PXR in the presence or absence of tetracycline (0.1 μg/ml).

Small interfering RNA and Transfection. HUVECs were transfected with PXR small interfering RNA (siRNA) (sense, 5'-CAGAGGCAAUUGGCAAUATT-3', antisense, 5'-UAAGGGCAUUGCCCAUUATT-3'), antisense, 5'-GCGUUCAGUUCUUACU-3', antiseense, 5'-AGUAAGAAGCAAGACCTT-3'), or scrambled siRNA (sense, 5'-UGGGUCUUGCCCAAGACGCAA-3', antisense, 5'-UGGGUCUUGCCCAAGACGCAA-3'), with Lipofectamine 2000 (Invitrogen). Experiments were performed with these cells at 24 hours after transfection.

Chromatin Immunoprecipitation Assay. HUVECs were treated with 1% formaldehyde for DNA-protein crosslinking, and then chromatin was sheared by sonication (three times × 15 seconds). Immunoprecipitations were performed with the use of a rabbit polyclonal antibody against NF-κB/p65 or control IgG and protein A/G Sepharose beads. After washing, the beads were eluted in elution buffer (1% SDS, 100 mM NaHCO3). DNA samples were extracted and purified after proteinase K digestion. The bound DNAs were amplised using qPCR with primers flanking the NF-κB binding sites in the human NLRP3 promoter regions (Table 1). Relative DNA binding was...
expressed as fold enrichment compared with immunoprecipitates using control IgG (Fan et al., 2008).

**Plasmids and Transfection.** The genomic fragment harboring 2977 to 1151 base pairs in relation to the transcription start site (Anderson et al., 2008) of the human NLRP3 gene was cloned using PCR from the genomic DNA. The primer sequences were 5'-CGGGCTAGCGGTCATAACGTAGTTCTA-3' (forward) and 5'-CGGCTCGAGGCCAGAAGAAATTCCTAG-3' (reverse). The amplified product was subcloned into a pGL3-basic plasmid containing the firefly luciferase (Luc) reporter gene (Promega, Madison, WI) with the use of NheI and XhoI restriction enzymes to generate NLRP3-Luc. The PXR-responsive element (PXRE)-Luc reporter plasmid pCMX-PXR and 5'/C2 NF-κB-Luc have been described previously (Wang et al., 2013). Plasmids were transfected into BAECs using Lipofectamine 2000. To normalize transfection efficiency, a plasmid expressing β-galactosidase (pRSV-gal) was cotransfected. Results were expressed as fold induction compared with basal promoter activity.

**Statistical Analysis.** Data are presented as the mean ± SD from at least three independent experiments. Data analysis was performed using Microsoft Excel (Microsoft, Redmond, WA) and GraphPad Prism (version 6; GraphPad Software, La Jolla, CA). Student’s t test (paired groups) or one-way analysis of variance followed by Newman-Keuls post hoc test (multigroup comparisons) were used to analyze the statistical significance. A P value of <0.05 was considered to be significant.

### Results

**Effects of Statins on ox-LDL- and TNFα-induced NLRP3 Inflammasome Activation in ECs.** Ox-LDL and TNFα are critical atherogenic mediators known to induce the expression of proinflammatory genes in ECs (Yokode, 2001; Zhang et al., 2009). To test the effects of ox-LDL and TNFα on the NLRP3 inflammasome in ECs, we treated HUVECs with various concentrations of ox-LDL (0 to ∼200 μg/ml) or TNFα (0 to ∼10 ng/ml) for 12 hours. Western blotting showed that both ox-LDL and TNFα dose-dependently increased the protein levels of NLRP3 and cleaved caspase-1 (Fig. 1A). A similar dose-dependent action was observed at the NLRP3 mRNA level as measured by using qRT-PCR (Fig. 1B). Next, we examined the effects of statins on NLRP3 inflammasome activation. We treated HUVECs with simvastatin (0.5 μM) or mevastatin (5 μM) for 12 hours before exposure to ox-LDL or TNFα. Western blotting showed that both ox-LDL and TNFα dose-dependently increased the protein levels of NLRP3 and cleaved caspase-1 (Fig. 1A). A similar dose-dependent action was observed at the NLRP3 mRNA level as measured by using qRT-PCR (Fig. 1B). Next, we examined the effects of statins on NLRP3 inflammasome activation. We treated HUVECs with simvastatin (0.5 μM) or mevastatin (5 μM) for 12 hours before exposure to ox-LDL or TNFα. As shown in Fig. 1C, simvastatin or mevastatin significantly inhibited the ox-LDL- or TNFα-induced increases in protein levels of NLRP3 and cleaved caspase-1. The mRNA level of NLRP3 was also decreased by the statins (Fig. 1D). Taken together, these results indicated that statins attenuate the activation of NLRP3 inflammasome induced by ox-LDL or TNFα in ECs.
Role of PXR in the Suppressive Effect of Statins on ox-LDL- or TNFα-Activated NLRP3 Inflammasome in ECs. Statins have been reported to activate PXR in liver cells (Howe et al., 2011; Hoffart et al., 2012; Pleée-Gautier et al., 2012). Thus, we examined the effect of statins on PXR in ECs. We cotransfected pCMX-PXR and PXRE-Luc into BAECs and then treated with atorvastatin, mevastatin, or simvastatin. As shown in Fig. 2B, these results indicated that statins can activate PXR in ECs.

We found that overexpression of PXR attenuated the NLRP3 inflammasome activation in response to ox-LDL or TNFα (Fig. 3C). Furthermore, PXR knockdown abrogated the suppressive effect of rifampicin on ox-LDL-induced NLRP3 inflammasome activation (Fig. 3, D and E). Taken together, these results suggested that PXR agonists inhibit ox-LDL- or TNFα-activated NLRP3 inflammasome in a PXR-dependent manner in ECs.

Role of the LOX-1/NF-κB Pathway in Activation of the NLRP3 Inflammasome by ox-LDL or TNFα. LOX-1 is the major receptor for ox-LDL in ECs and is thought to be a marker of endothelial dysfunction in many cardiovascular diseases (Pirillo et al., 2013; Ulrich-Merzenich and Zeitler, 2013). LOX-1 expression was increased after ox-LDL or TNFα exposure (Supplemental Fig. 1). Knockdown of LOX-1 in ECs attenuated the activation of NLRP3 inflammasome induced by ox-LDL (Fig. 4, A and B). These results indicated an important role of LOX-1 in ox-LDL activation of the NLRP3 inflammasome in ECs. It has been previously shown (Hu et al., 2008) that ox-LDL binding to endothelial LOX-1 can activate the NF-κB signal pathways. We investigated whether NF-κB was also involved in ox-LDL- or TNFα-induced NLRP3 inflammasome activation. HUVECs were infected with Ad-Lac or Ad-IκBα for 24 hours and then stimulated with ox-LDL or TNFα for 12 hours. Protein levels of NLRP3 and caspase-1 were assessed by Western blotting. These results indicated that the LOX-1/NF-κB pathway contributes to the activation of the NLRP3 inflammasome by ox-LDL or TNFα.

Role of the LOX-1/NF-κB Pathway in the Effects of Statins on the NLRP3 Inflammasome. To investigate whether statins attenuate NLRP3 inflammasome activation by inhibiting the LOX-1/NF-κB pathway, we pretreated ECs with atorvastatin and then exposed to ox-LDL. As shown in Fig. 5, A and B, ox-LDL increased LOX-1 expression; this response was significantly diminished by simvastatin or mevastatin. Similarly, PXR agonists (rifampicin and SR12813) or the overexpression of PXR also decreased protein
and mRNA levels of LOX-1 (Fig. 5, C and D). Furthermore, PXR knockdown abolished the suppressive effects of statins and rifampicin on LOX-1 expression (Fig. 5, E–H). Taken together, these results indicated an inhibitory effect of PXR on LOX-1 expression.

LOX-1 activation results in the excessive generation of ROSs, which are known to trigger the activation of the NLRP3 inflammasome (Schroder and Tschopp, 2010). We found that simvastatin or mevastatin significantly reduced ROS generation in response to TNFα (Supplemental Fig. 2). Furthermore, the PXR agonists rifampicin and SR12813 also decreased NF-κB activation by ox-LDL or TNFα (Supplemental Fig. 3). Thus, these results suggested that PXR inhibition of ROSs may contribute to the inhibitory effects of statins on activation of the LOX-1/NF-κB pathway and the NLRP3 inflammasome.

Effects of Statins on PXR Inhibition of NF-κB Binding to the NLRP3 Promoter. Since NF-κB plays a central role in the transcriptional regulation of the NLRP3 gene and PXR suppressed activation of NF-κB target genes (Gu et al., 2006; Xie and Tian, 2006; Qiao et al., 2012), we examined the effects of statin-activated PXR on NF-κB binding activity to the human NLRP3 promoter. Bioinformatics analysis using the Transcription Element Search System (http://www.cbil.upenn.edu/cgi-bin/tess/tess) revealed three canonical NF-κB–responsive elements in the 5'-flanking region of the human NLRP3 gene (Fig. 6A). Chromatin immunoprecipitation (ChIP) assays demonstrated that both ox-LDL and TNFα increased NF-κB binding at these motifs and that these responses were inhibited by mevastatin (Fig. 6B) or SR12813 (Fig. 6C). Furthermore, we performed the NLRP3 promoter reporter assay in BAECs. As shown in Fig. 6D, TNFα increased the NLRP3-Luc reporter activity, which was inhibited by SR12813. These results indicated that the statin-activated PXR inhibits NF-κB binding to the NLRP3 promoter in ECs.

Discussion

In this study, we demonstrated for the first time that statins can inhibit ox-LDL- or TNFα-induced NLRP3 inflammasome activation in ECs and that this inhibitory effect is mediated by activation of the xenobiotic nuclear receptor PXR.

A variety of intracellular and extracellular stimuli have been known to trigger the activation of NLRP3 inflammasomes. Such “danger” signals include microbial components, ATP, glucose, cholesterol crystal, hyaluronan, and ROS (Jin and Flavell, 2010; Sutterwala et al., 2014). As part of an innate immunity system, the NLRP3 inflammasome is essential to the maintenance of homeostasis against pathogens and...
xenobiotics. However, excessive activation of inflammasomes may lead to tissue damage and is implicated in proinflammatory diseases (Kim and Jo, 2013). Cholesterol crystals and ox-LDL activate NLRP3 inflammasome in macrophages and play pathologic roles in atherosclerosis (Duewell et al., 2010; Sheedy et al., 2013). A randomized clinical study (Satoh et al., 2014) has shown that mRNA and protein levels of NLRP3 in peripheral blood mononuclear cells are higher in the CAD patients and are positively correlated with the plasma levels of IL-1β and IL-18. Interestingly, NLRP3 and IL-1β/IL-18 levels were significantly reduced after treatment with atorvastatin for 8 months. In the current study, we found that ox-LDL and TNFα triggered NLRP3 inflammasome activation in ECs and, most importantly, that statins inhibited ox-LDL- or TNF-α-triggered NLRP3 inflammasome activation (Fig. 1).

One of the important findings in this study is that PXR plays a critical role in the suppression of TNFα- and ox-LDL-induced NLRP3 inflammasome activation in human ECs. This notion is supported by the following results: 1) statins (simvastatin, mevastatin, and atorvastatin) activated the PXR reporter and endogenous target gene MDR1 in ECs (Fig. 2, A and B); and 2) gene silencing of PXR abrogated the suppressive effect of statin on NLRP3 inflammasome (Fig. 2, C and D), whereas PXR agonists or overexpression of PXR elicited similar effects (Fig. 3, A–C). It is worth noting that the pharmacologic actions of PXR are highly divergent across species (Zhou et al., 2009). The species divergence may be explained by the low homology in the ligand-binding domain, where human and mouse genes share less than 80% in amino acid sequences (Zhou et al., 2009). Thus, we used rifampicin and SR12813, two potent agonists for human PXR with little agonism toward rodent PXR (Jones et al., 2000).

Atherogenic effects of LOX-1 have been well established and are involved in endothelial dysfunction, foam cell formation, platelet activation, and plaque instability (Pirillo et al., 2013). Expression of LOX-1 can be induced in response to many atherogenic stimuli, including TNFα, angiotensin II, endothelin-1, free radicals, and ox-LDL (Pirillo et al., 2013). LOX-1 activation leads to ROS generation, mitochondrial DNA damage, and the induction of NLRP3 expression in THP-1 cells (Ding et al., 2014). We found that LOX-1 was essential for ox-LDL-triggered NLRP3 inflammasome activation in ECs (Fig. 4, A and B). Activation of LOX-1 by ox-LDL triggers the NF-κB signaling pathway (Matsunaga et al., 2003; Mattaliano et al., 2009). Here, we demonstrated that the PXR activation by treatment with either statins or rifampicin, or by PXR overexpression, inhibited LOX-1 expression (Fig. 5, A–D). Conversely, knockdown of PXR diminished the inhibitory effects of statins and rifampicin on LOX-1 (Fig. 5, E–H), indicating that statins inhibit LOX-1

![Fig. 6. Effects of statins and PXR on NF-κB binding to the NLRP3 promoter. (A) The diagram depicts putative NF-κB motifs in the 5′-flanking region of the human NLRP3 gene. HUVECs were treated with ox-LDL (B) or TNFα (C) in the presence or absence of mevastatin (Mev) or simvastatin (SR). ChIP assays were performed with NF-κB/p65 antibody or IgG as a negative control. Immunoprecipitated DNA was eluted and amplified by PCR using specific primers flanking the NF-κB sites. PCR results were expressed as fold change compared with IgG control. (D) BAECs were cotransfected with NLRP3-Luc plasmid then were exposed to SR for 12 hours before incubating with TNFα. Luc activity was measured and normalized to β-gal activity. Data represent the mean ± SD, n = 4, **P < 0.01 versus control; ##P < 0.01 versus TNFα.](http://molpharm.aspetjournals.org)
expression in a PXR-dependent manner. These results suggest that inhibition of LOX-1/NF-κB is a key mechanism by which statin/PXR signaling inhibits ox-LDL- or TNFα-induced NLRP3 inflammasome activation in ECs (Fig. 4, C and D). This finding is consistent with the previously described reciprocal inhibition between PXR and NF-κB pathways (Zhou et al., 2006). In light of the well-established roles of NF-κB in atherogenesis (Baker et al., 2011) and the pleotropic effects of statins on endothelial proinflammatory response (Greenwood and Mason, 2007), the PXR/NF-κB/NLRP3 inflammasome signaling pathway may represent a novel mechanism underlying the atheroprotective actions of statins.

Intriguingly, our previous study (Wang et al., 2014) showed that PXR has recurrent cis-elements in the regulatory regions of NLRP3 genes that, when activated, can transcriptionally induce the expression of NLRP3. Such a mechanism may play an important role in the maintenance of vascular homeostasis by coupling endothelial detoxification with immune surveillance program against the xenobiotics and concurrent tissue injury. On the other hand, athrogenic stimuli provoke excessive expression of NLRP3 and a much concurrent tissue injury. On the other hand, athrogenic stimuli provoke excessive expression of NLRP3 and a much excessive expression of NLRP3 in ECs (Fig. 4, C and D). This finding is consistent with the previously described reciprocal inhibition between PXR and NF-κB pathways (Zhou et al., 2006). In light of the well-established roles of NF-κB in atherogenesis (Baker et al., 2011) and the pleotropic effects of statins on endothelial proinflammatory response (Greenwood and Mason, 2007), the PXR/NF-κB/NLRP3 inflammasome signaling pathway may represent a novel mechanism underlying the atheroprotective actions of statins.


Address correspondence to: Dr. Naping Wang, The Advanced Institute for Medical Sciences, Dalian Medical University, Dalian 116044, People’s Republic of China. E-mail: nanpingwang2003@yahoo.com or Dr. Lei Xiao, Cardiovascular Research Center, Xi’an Jiaotong University, Xi’an 710061, People’s Republic of China. E-mail: xiaolei0122@xjtu.edu.cn